GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Imidex and Spesana Announce Partnership to Transform Lung Cancer Detection

NextEdge Admin

14 Jul 2024

2 min 13 sec

Spesana, a leader in personalized medicine technology for clinicians and labs, and Imidex, developer of the FDA-cleared VisiRad XR, are excited to announce their strategic partnership aimed at improving lung cancer detection and patient care. This collaboration will leverage a clinical study to assess the impact of AI on identifying lung nodules and masses in chest X-rays.

By integrating VisiRad XR’s advanced detection algorithm with Spesana’s cutting-edge medical data platform, the partnership aims to uncover additional lung nodules and masses during routine care. This initiative will not only enhance lung cancer detection rates but also identify at-risk patients for clinical trials and explore the potential of liquid biopsies.

Lung cancer remains the leading cause of cancer deaths in the U.S., often diagnosed too late for effective treatment. VisiRad XR’s technology offers a vital second-read capability for radiologists, achieving 83% sensitivity in detecting often-missed findings. This collaboration will broaden access to AI-driven insights across healthcare providers.

Spesana’s platform streamlines patient referrals and enhances clinical workflows through real-time collaboration and data-driven decision support. By integrating VisiRad XR, Spesana aims to empower healthcare providers with comprehensive patient views and efficient care pathways.

“Together, we envision a future where lung cancer is detected early, allowing for timely treatment and improved patient outcomes,” said Carla Balch, CEO of Spesana, underscoring the partnership's commitment to advancing precision medicine.